Differences in components and anti-inflammatory and analgesic activities of two phase states of Wuzhuyu Decoction.
10.19540/j.cnki.cjcmm.20240719.301
- Author:
Qi WANG
1
;
Mei-Jing LI
1
;
Xiao-Meng GUO
1
;
Ze-Kuan ZHANG
1
;
Nan ZHANG
1
;
Zhi-Min WANG
2
;
Mu-Xin GONG
1
Author Information
1. School of Traditional Chinese Medicine, Capital Medical University Beijing 100069, China Beijing Key Laboratory of Traditional Chinese Medicine Collateral Disease Theory Research Beijing 100069, China.
2. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.
- Publication Type:Journal Article
- Keywords:
LC-MS/MS;
Wuzhuyu Decoction;
active components;
analgesic;
anti-inflammatory;
nano;
network pharmacology;
phase
- MeSH:
Animals;
Analgesics/pharmacology*;
Drugs, Chinese Herbal/pharmacology*;
Mice;
Anti-Inflammatory Agents/pharmacology*;
Male;
Chromatography, High Pressure Liquid;
Tandem Mass Spectrometry;
Pain/drug therapy*;
Humans
- From:
China Journal of Chinese Materia Medica
2024;49(21):5865-5876
- CountryChina
- Language:Chinese
-
Abstract:
This study rapidly identified and quantified the chemical components of the Wuzhuyu Decoction nanophase(WZYD-N) and suspension phase(WZYD-S) using ultra-high performance liquid chromatography coupled with triple quadrupole mass spectrometry(UPLC-QQQ-MS/MS). Based on preliminary pharmacodynamic experiments and network pharmacology analysis, the differential anti-inflammatory and analgesic activities of WZYD-N and WZYD-S were explored to understand their pharmacodynamic basis. WZYD-N and WZYD-S were separated by differential centrifugation-dialysis, and their particle size, Zeta potential, PDI, and morphology were characterized by dynamic light scattering and transmission electron microscopy. A method was established to quantify 23 representative components of WZYD using UPLC-QQQ-MS/MS, clarifying the differences in component content between the two phases. The anti-inflammatory and analgesic activities of WZYD-N and WZYD-S were preliminarily investigated using the acetic acid-induced enhanced capillary permeability inflammation model and the acetic acid writhing pain model. Network pharmacology was applied to screen the key anti-inflammatory and analgesic targets and active components of WZYD, and the relationship between the components and pharmacodynamics of WZYD-N and WZYD-S was analyzed based on quantitative results. The results showed that WZYD-N primarily consisted of spherical self-assembled aggregates around 200 nm, with a PDI of approximately 0.299 and a zeta potential of-22.1 mV. With an equivalent amount of crude drugs, obacunone and dihydroevocarpine were quantified in equal amounts in WZYD-N and WZYD-S. The content of rutaecarpine, evocarpine, rutaevine, limonin, and ginsenoside Ro was higher in WZYD-S, while 15 other components, including evodiamine, dehydroevodiamine, ginsenoside Re, 6-gingerol, and ginsenoside Rg_1, were higher in WZYD-N. Moreover, 6-dehydrogingerdione was low in both WZYD-N and WZYD-S. Preliminary pharmacodynamic experiments showed that WZYD-N could reduce the number of writhing responses and inhibit pain responses induced by acetic acid in mice, exhibiting analgesic effects similar to the WZYD group. WZYD-S could reduce the absorbance value of the intraperitoneal lavage fluid in mice, exhibiting anti-inflammatory effects comparable to the WZYD group. Network pharmacology analysis indicated that dehydroevodiamine, rutaecarpine, 6-gingerol, and ginsenoside Rg_1 might be the analgesic active components of WZYD, and limonin, rutaevine, and ginsenoside Ro might be the anti-inflammatory active components of WZYD. This study proposed a novel strategy for elucidating the pharmacodynamic basis of WZYD and innovating classical formulas.
